IHH Healthcare has announced impressive financial results for the second quarter of 2024, showcasing significant double-digit growth across key metrics. The group's revenue surged by 30% to RM6.1 billion, while EBITDA rose 34% to RM1.4 billion. Profit After Tax and Minority Interests (PATMI), excluding exceptional items, increased by 39% to RM437 million. PATMI, including all items, more than doubled to RM623 million.

For the first half of 2024, IHH Healthcare continued its strong performance with a 23% rise in revenue to RM12.0 billion and a 26% increase in EBITDA to RM2.7 billion. PATMI, excluding exceptional items, grew by 30% to RM840 million. However, PATMI, including all items, fell by 18% due to a high base last year, which benefited from RM862 million in one-off gains from the sale of International Medical University (IMU).

Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare, commented, "We have delivered an outstanding performance in the first half of 2024, marked by two consecutive quarters of record revenue and strong operational excellence. Our focus on providing quality patient care and excellent outcomes remains paramount. Our recent initiatives, including the launch of IHH Singapore's first transitional care facility and Fortis Memorial Research Institute's new Gamma Knife Esprit treatment, further solidify our position as a leader in healthcare."

The group's operational summary for Q2 2024 highlights sustained growth, with revenue and EBITDA reflecting strong patient volume and complex case management across all markets. PATMI more than doubled, driven by strong operational performance, deferred tax credits, and net monetary gains from applying MFRS 129. Excluding exceptional items, PATMI (ex EI) saw a 39% increase.

IHH Healthcare has recently made strategic appointments to its Board of Directors, including Tan Sri Dr Nik Norzrul Thani Nik Hassan Thani as Chairman and Independent Non-Executive Director, and Chua Bin Hwee as Audit Committee Chairman and Independent Non-Executive Director. Additionally, the group has expanded its facilities and capabilities, such as breaking ground on TCF@East, IHH Singapore's first transitional care facility, and introducing Gamma Knife Esprit at Fortis Memorial Research Institute.